Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/53180
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNaidoo M.-
dc.contributor.authorMcnally O.-
dc.contributor.authorScott C.-
dc.contributor.authorFriedlander M.-
dc.contributor.authorCohen P.-
dc.contributor.authorPerera S.-
dc.contributor.authorBrand A.-
dc.contributor.authorRichardson G.-
dc.contributor.authorBunting M.-
dc.contributor.authorMohan R.-
dc.contributor.authorOehler M.-
dc.contributor.authorHyde S.-
dc.contributor.authorJobling T.-
dc.contributor.authorFarrell R.-
dc.contributor.authorEvans S.-
dc.contributor.authorRome R.-
dc.contributor.authorZalcberg J.-
dc.date.accessioned2025-02-17T05:16:52Z-
dc.date.available2025-02-17T05:16:52Z-
dc.date.copyright2024-
dc.date.issued2025-02-07en
dc.identifier.citationInternational Journal of Gynecological Cancer. Conference: International Gynecologic Cancer Society Annual Meeting, IGCS 2024. Dublin Ireland. 34(Supplement 3) (pp A240), 2024. Date of Publication: 01 Oct 2024.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/53180-
dc.description.abstractIntroduction Ovarian cancer (OC) in Australia has the highest gynaecological cancer mortality. Data on patterns of care (POC) compared with 'best practice' is limited. This study aims to describe POC and overall survival (OS) for women with newly diagnosed OC using data from the Australian National Gynae-Oncology Registry (NGOR). Methods Clinical Quality Indicators (CQIs) reflecting 'best practice' were sourced from the NGOR sites for all patients with newly diagnosed OC between 2017-2024. Results A total of 2643 OC patients were analysed. Across the 15 CQIs, the highest compliance included the proportion of patients discussed at a multi-disciplinary meeting (n=2543, 96%) and diagnosed by cytology or histology (n=747, 89%) prior to commencing neoadjuvant chemotherapy. In a multivariate analysis, the CQIs associated with significantly improved rates of OS were in patients receiving doublet chemotherapy, genetic testing, and in patients who had primary or interval debulking surgery with no macroscopic residual disease. Overall survival acrosss all stages at 3-years and 5- years was 66% and 50% respectively. Survival by stage is shown below: Conclusion/Implications This is the most comprehensive country- wide analysis demonstrating POC compliance with contemporary 'best practice' in Australia. Reporting of CQIs will likely result in improved outcomes for women with newly diagnosed OC.-
dc.publisherBMJ Publishing Group-
dc.relation.ispartofInternational Journal of Gynecological Cancer-
dc.subject.meshcytology-
dc.subject.meshgenital tract cancer-
dc.subject.meshgenetic screening-
dc.subject.meshneoadjuvant chemotherapy-
dc.subject.meshovary cancer-
dc.titlePatterns of ovarian cancer care and overall survival in Australia: a prospective study from the national gynae-oncology registry (NGOR).-
dc.typeConference Abstract-
dc.identifier.affiliationOncology-
dc.description.conferencenameInternational Gynecologic Cancer Society Annual Meeting, IGCS 2024-
dc.description.conferencelocationDublin, Ireland-
dc.type.studyortrialObservational study (cohort, case-control, cross sectional, or survey)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1136/ijgc-2024-IGCS.425-
local.date.conferencestart2024-10-16-
dc.identifier.institution(Naidoo, Perera, Richardson, Zalcberg) Monash University, Cancer Research Program, Monash University Public Health and Preventive Medicine, Melbourne, Australia-
dc.identifier.institution(Mcnally) Royal Women's Hospital, Oncology and Dysplasia Service, Melbourne, Australia-
dc.identifier.institution(Scott) Sir Peter MacCallum Cancer Centre, Medical Oncology, Melbourne, Australia-
dc.identifier.institution(Friedlander) Prince of Wales and Royal Hospital for Women, Department of Medical Oncology, Sydney, Australia-
dc.identifier.institution(Cohen) University of Western Australia, Perth, Australia-
dc.identifier.institution(Brand) Westmead Hospital, Gynaecology Oncology, Sydney, Australia-
dc.identifier.institution(Bunting) Royal Hobart Hospital, Gynaecology Oncology, Hobart, Australia-
dc.identifier.institution(Mohan) St John of God Healthcare, Gynaecology Oncology, West Leederville, Australia-
dc.identifier.institution(Oehler) Royal Adelaide Hospital, Gynaecological Oncology, Adelaide, Australia-
dc.identifier.institution(Hyde) Mercy Hospital for Women, Gynaecology Oncology, Melbourne, Australia-
dc.identifier.institution(Jobling) Monash Health, Gynaecology Oncology, Melbourne, Australia-
dc.identifier.institution(Farrell) Chris O'Brien Lifehouse, Gynae-oncology, Camperdown, Australia-
dc.identifier.institution(Evans) Cancer Council Victoria, Victorian Cancer Registry Division, Melbourne, Australia-
dc.identifier.institution(Rome) Epworth Hospital, Gynaecology Oncology, East Melbourne, Australia-
local.date.conferenceend2024-10-18-
dc.identifier.affiliationmh(Jobling) Monash Health, Gynaecology Oncology, Melbourne, Australia-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeConference Abstract-
item.cerifentitytypePublications-
crisitem.author.deptObstetrics and Gynaecology (Monash Women's)-
Appears in Collections:Conferences
Show simple item record

Page view(s)

2
checked on Feb 22, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.